Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY001 in Advanced Solid Tumors
NCT06562647Phase 1Recruiting
- Sponsor
- CellOrigin Biotech
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SY001 in ovarian cancer and pancreatic cancer (PC), sponsored by CellOrigin Biotech. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Apr 2023; status: recruiting.
02
Drugs
SY001
03
Conditions
ovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06562647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562647.